AbbVie’s Viekira Pak (ombitasvir/paritaprevir/ritonavir; dasabuvir) cured all people with genotype 1b of hepatitis C virus (HCV) and compensated cirrhosis in a recent late-stage trial. The phase IIIb TURQUOISE-III study gave 12 weeks of the therapy to 60 participants, including both treatment-naive and treatment-experienced individuals. Researchers presented results at the 15th Annual International Symposium on Viral Hepatitis and Liver Diseases in Berlin, Germany.
All 60 of the participants achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure).
No participants stopped treatment because of adverse side effects. The most commonly reported side effects, with a greater than 10 percent frequency, were fatigue (22 percent), diarrhea (20 percent) and headache (18 percent).
To read a press release on the study, click here: prnewswire.co.uk/news-relea...